Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT

被引:0
|
作者
Geerts, Julie F. M. [1 ,2 ]
van der Zijden, Charlene J. [2 ]
van der Sluis, Pieter C. [2 ]
Spaander, Manon C. W. [3 ]
Nieuwenhuijzen, Grard A. P. [1 ]
Rosman, Camiel [4 ]
van Laarhoven, Hanneke W. M. [5 ,6 ]
Verhoeven, Rob H. A. [5 ,6 ,7 ]
Wijnhoven, Bas P. L. [2 ]
Lagarde, Sjoerd M. [2 ]
Mostert, Bianca [8 ]
机构
[1] Catharina Hosp, Dept Surg, NL-5623 EJ Eindhoven, Netherlands
[2] Erasmus MC, Dept Surg, Canc Inst, NL-3015 GD Rotterdam, Netherlands
[3] Erasmus MC, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands
[4] Radboud Univ Nijmegen, Dept Surg, Med Ctr, NL-6525 GA Nijmegen, Netherlands
[5] Univ Amsterdam, Dept Med Oncol, Amsterdam UMC Locat, NL-1081 HV Amsterdam, Netherlands
[6] Canc Ctr Amsterdam, Canc Treatment & Qual Life, NL-1105 AZ Amsterdam, Netherlands
[7] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, NL-3511 LC Utrecht, Netherlands
[8] Erasmus MC, Dept Med Oncol, Canc Inst, NL-3015 GD Rotterdam, Netherlands
关键词
esophageal cancer; gastro-esophageal cancer; gastric cancer; neoadjuvant chemotherapy; esophagectomy; STAGING LAPAROSCOPY; ADENOCARCINOMA; SURVIVAL; 5-FLUOROURACIL; CAPECITABINE; OXALIPLATIN;
D O I
10.3390/cancers16071291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The FLOT4-AIO trial (2019) showed improved survival with perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) compared to anthracyclin triplets in gastric cancer treatment. It is unclear whether these results extend to real-world scenarios in the Netherlands. This study aimed to compare outcomes of perioperative FLOT to anthracyclin triplets in a real-world Dutch gastric cancer population. Methods: Patients diagnosed with resectable (cT2-4a/cTxN0-3/NxM0) gastric or gastro-esophageal junction carcinoma between 2015-2021 who received neoadjuvant FLOT or anthracyclin triplets were selected from the Netherlands Cancer Registry. The primary outcome was overall survival (OS), analyzed through multivariable Cox regression. Secondary outcomes included pathological complete response (pCR), neoadjuvant chemotherapy cycle completion, surgical resection rates, and adjuvant therapy. Results: Adjusted OS showed no significant survival benefit (HR = 0.88, 95% CI 0.77-1.01, p = 0.07), even though the median OS was numerically improved by 8 months with FLOT compared to anthracyclin triplets (48.1 vs. 39.9 months, p = 0.16). FLOT patients were more likely to undergo diagnostic staging laparoscopies (74.2% vs. 44.1%, p < 0.001), had higher rates of completing neoadjuvant chemotherapy (OR = 1.35, 95% CI 1.09-1.68, p = 0.007), receiving adjuvant therapy (OR = 1.34, 95% CI 1.08-1.66, p = 0.08), and achieving pCR (OR = 1.52, 95% CI 1.05-2.20, p = 0.03). No significant differences were observed in (radical) resection rates. Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Cryotherapy in Combination With Systemic Chemotherapy for Gastro-Esophageal Cancer Palliation: Chilling Initial Results
    Kachaamy, Toufic
    Shah, Tilak
    Weber, Jeffrey
    Sangal, Ashish
    Zfass, Alvin M.
    Kundranda, Madappa N.
    GASTROINTESTINAL ENDOSCOPY, 2015, 81 (05) : AB519 - AB519
  • [32] Comparison of perioperative chemotherapy and neoadjuvant chemoradiation in patients with adenocarcinoma of the gastro-esophageal junction: a population-based evaluation of the Munich Cancer Registry
    Muench, S.
    Habermehl, D.
    Agha, A.
    Belka, C.
    Combs, S. E.
    Eckel, R.
    Friess, H.
    Gerbes, A.
    Nuessler, N. C.
    Schepp, W.
    Schmid, R. M.
    Schmitt, W.
    Schubert-Fritschle, G.
    Weber, B.
    Werner, J.
    Engel, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S33 - S34
  • [33] Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
    Zeng, Hanqing
    Wang, Chunjiang
    Song, Li-Ying
    Jia, Su-Jie
    Zeng, Xiaohui
    Liu, Qiao
    BMJ OPEN, 2022, 12 (11):
  • [34] RADIONUCLIDE STUDIES FOR GASTRO-ESOPHAGEAL REFLUX AND GASTRIC-EMPTYING
    HAYDEN, PW
    BLUMHAGEN, JB
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 1984, 26 (02): : 242 - 242
  • [35] Mesothelin Expression and Its Clinicopathological and Prognostic Significance in Gastric and Gastro-Esophageal Junction Cancer
    Santos-Sousa, Hugo
    Marcos-Silva, Lara
    Pinto-de-Sousa, Joao
    David, Leonor
    Costa-Maia, Jose
    GASTROENTEROLOGY, 2013, 144 (05) : S1136 - S1136
  • [36] GASTRIC-ULCERATION AFTER FUNDOPLICATION FOR GASTRO-ESOPHAGEAL REFLUX
    GAY, RJ
    TURNER, LJ
    DOUBEK, LJ
    IRISH JOURNAL OF MEDICAL SCIENCE, 1982, 151 (06) : 190 - 191
  • [37] ROLE OF GASTRIC ACIDIFICATION BY VAGOSERINE IN TREATMENT OF GASTRO-ESOPHAGEAL REFLUX
    CHEVREL, B
    MEDECINE & CHIRURGIE DIGESTIVES, 1980, 9 (03): : 265 - 268
  • [38] DELAYED GASTRIC-EMPTYING WITH GASTRO-ESOPHAGEAL REFLUX - REPLY
    HILLEMEIER, C
    GRYBOSKI, J
    JOURNAL OF PEDIATRICS, 1981, 99 (04): : 669 - 670
  • [39] DELAYED GASTRIC-EMPTYING IN INFANTS WITH GASTRO-ESOPHAGEAL REFLUX
    HILLEMEIER, AC
    LANGE, R
    MCCALLUM, R
    SEASHORE, J
    GRYBOSKI, J
    JOURNAL OF PEDIATRICS, 1981, 98 (02): : 190 - 193
  • [40] Perioperative versus total neoadjuvant chemotherapy in gastric cancer
    Yang, Jessica
    Greally, Megan
    Strong, Vivian E.
    Coit, Daniel G.
    Chou, Joanne F.
    Capanu, Marinela
    Maron, Steven B.
    Kelsen, David P.
    Ilson, David H.
    Janjigian, Yelena Y.
    Ku, Geoffrey Y.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (03) : 1193 - +